BioHarvest Sciences (CNSX:BHSC) - Share price, News & Analysis

BHSC fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

BHSC Stock Overview

BioHarvest Sciences Inc., together with its subsidiaries, offers nutraceutical super fruits and cannabis verticals in Israel and internationally.

Risk Analysis

Earnings have declined by 25% per year over past 5 years

Shareholders have been diluted in the past year

Does not have meaningful revenue ($2M)

BioHarvest Sciences Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioHarvest Sciences
Historical stock prices
Current Share Price	CA$0.30
52 Week High	CA$0.54
52 Week Low	CA$0.25
Beta	0.78
1 Month Change	-14.29%
3 Month Change	-21.05%
1 Year Change	-10.45%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	100.00%

Shareholder Returns

	BHSC	CA Food	CA Market
7D	5.3%	0.6%	1.3%
1Y	-10.4%	-27.9%	4.8%

Return vs Industry: BHSC exceeded the Canadian Food industry which returned -25.1% over the past year.

Return vs Market: BHSC underperformed the Canadian Market which returned 5.9% over the past year.

Price Volatility

Is BHSC's price volatile compared to industry and market?
BHSC volatility
BHSC Average Weekly Movement	5.1%
Food Industry Average Movement	9.0%
Market Average Movement	9.7%
10% most volatile stocks in CA Market	16.7%
10% least volatile stocks in CA Market	4.3%

Stable Share Price: BHSC is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: BHSC's weekly volatility has decreased from 10% to 5% over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Ilan Sobel	https://www.bioharvest.com

BioHarvest Sciences Inc., together with its subsidiaries, offers nutraceutical super fruits and cannabis verticals in Israel and internationally. Its plant cell growth technology produces the active secondary metabolites without the need to grow the plant itself. The company designs, develops, manufactures, and markets Vinia, a red grape powder nutraceutical product; and medical cannabis.

BioHarvest Sciences Fundamentals Summary

How do BioHarvest Sciences's earnings and revenue compare to its market cap?
BHSC fundamental statistics
Market Cap	US$106.01m
Earnings (TTM)	-US$9.83m
Revenue (TTM)	US$2.10m

50.5x

P/S Ratio

-10.8x

P/E Ratio

Is BHSC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
BHSC income statement (TTM)
Revenue	US$2.10m
Cost of Revenue	US$1.43m
Gross Profit	US$670.00k
Other Expenses	US$10.50m
Earnings	-US$9.83m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.022
Gross Margin	31.87%
Net Profit Margin	-467.51%
Debt/Equity Ratio	0%

How did BHSC perform over the long term?

See historical performance and comparison

Valuation

Is BioHarvest Sciences undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

37.17x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BHSC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BHSC's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: BHSC is unprofitable, so we can't compare its PE Ratio to the Canadian Food industry average.

PE vs Market: BHSC is unprofitable, so we can't compare its PE Ratio to the Canadian market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BHSC's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: BHSC is overvalued based on its PB Ratio (37.2x) compared to the CA Food industry average (1.9x).

Future Growth

How is BioHarvest Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

50.0%

Forecasted Food, Beverage & Tobacco industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioHarvest Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has BioHarvest Sciences performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-25.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BHSC is currently unprofitable.

Growing Profit Margin: BHSC is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: BHSC is unprofitable, and losses have increased over the past 5 years at a rate of 25% per year.

Accelerating Growth: Unable to compare BHSC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BHSC is unprofitable, making it difficult to compare its past year earnings growth to the Food industry (-22.1%).

Return on Equity

High ROE: BHSC has a negative Return on Equity (-344.2%), as it is currently unprofitable.

Financial Health

How is BioHarvest Sciences's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BHSC's short term assets ($5.7M) exceed its short term liabilities ($2.9M).

Long Term Liabilities: BHSC's short term assets ($5.7M) exceed its long term liabilities ($4.4M).

Debt to Equity History and Analysis

Debt Level: BHSC is debt free.

Reducing Debt: BHSC had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BHSC has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: BHSC is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.

Dividend

What is BioHarvest Sciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BHSC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BHSC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BHSC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BHSC's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BHSC has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Food, Beverage & Tobacco industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure

CEO

Ilan Sobel

1.92yrs

Tenure

US$684,312

Compensation

Mr. Ilan Sobel has been the Chief Executive Officer at BioHarvest Sciences Inc. since June 9, 2020. He served as Chief Operating Officer at Weissbeerger Ltd. and then Chief Commercial Officer of Weissbeerg...

Leadership Team

Experienced Management: BHSC's management team is considered experienced (2.8 years average tenure).

Board Members

Experienced Board: BHSC's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.3%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/18 00:00
End of Day Share Price	2022/05/18 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31